The estimated Net Worth of Henry C. Rath is at least $44.3 Mille dollars as of 3 August 2022. Henry Rath owns over 5,676 units of Surface Oncology Inc stock worth over $34,587 and over the last 3 years Henry sold SURF stock worth over $9,763.
Henry has made over 1 trades of the Surface Oncology Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Henry sold 5,676 units of SURF stock worth $9,763 on 3 August 2022.
The largest trade Henry's ever made was selling 5,676 units of Surface Oncology Inc stock on 3 August 2022 worth over $9,763. On average, Henry trades about 1,135 units every 0 days since 2021. As of 3 August 2022 Henry still owns at least 32,324 units of Surface Oncology Inc stock.
You can see the complete history of Henry Rath stock trades at the bottom of the page.
Henry's mailing address filed with the SEC is C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE, MA, 02139.
Over the last 6 years, insiders at Surface Oncology Inc have traded over $69,198,912 worth of Surface Oncology Inc stock and bought 2,836,996 units worth $42,496,090 . The most active insiders traders include Forest Baskett, Scott D Sandell e Anthony A. Jr. Florence. On average, Surface Oncology Inc executives and independent directors trade stock every 37 days with the average trade being worth of $156,856. The most recent stock trade was executed by Alison Oneill on 1 August 2023, trading 7,042 units of SURF stock currently worth $6,619.
surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww
Surface Oncology Inc executives and other stock owners filed with the SEC include: